Utility values for pre-menopausal women suffering from symptomatic uterine fibroids

References

• Donnez J, Tomaszewski J, Vizquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366:421-32
   PubMed Web of Science ®Google Scholar
• Harding G, Coyne K, Thompson C, Spies J. The responsiveness of the uterine fibroid symptom and health-related quality of life questionnaire (UFS-QOL). Health Qual Life Out 2008;6:1-8
   PubMed Web of Science ®Google Scholar
• Chen CR, Buck GM, Courey NG, et al. Risk factors for uterine fibroids among women undergoing tubal sterilization. Am J Epidemiol 2001;153:20-6
   PubMed Web of Science ®Google Scholar
• Marino JL, Eskenazi B, Warner M, et al. Uterine leiomyoma and menstrual cycle characteristics in a population-based cohort study. Hum Reprod 2004;19:2350-5
   PubMed Web of Science ®Google Scholar
• Day Baird D, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2004;188:100-7
   Web of Science ®Google Scholar
• Pron G, Cohen M, Soucie J, et al. The Ontario uterine fibroid embolization trial. Part 1. Baseline patient characteristics, fibroid burden, and impact on life. Fertil Steril 2003;79:112-19
   PubMed Web of Science ®Google Scholar
• Hirst A, Dutton S, Wu O, et al. A multi-centre retrospective cohort study comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine artery embolization for the treatment of symptomatic uterine fibroids. The HOPEFUL study Health Technol Assess 2008;12:1-248
   PubMed Web of Science ®Google Scholar
• Vilos GA, Vilos AG, Ferrazzi S. Symptomatic uterine fibroids (UFs) are common in pre-menopausal Canadian women and lead to reduced quality of life (QoL) across multiple domains. Proceedings to the 70th Annual Clinical and Scientific Conference; The Society of Obstetricians and Gynaecologists of Canada. Niagara Falls, ON, CA; 2014. P-GYN-MD-019
   Google Scholar
• Kuppermann M, Learman LA, Schembri M, et al. Effect of noncancerous pelvic problems on health-related quality of life and sexual functioning. Obstet Gynecol 2013;111:633-42
   Google Scholar
• Carls GS, Lee DW, Ozminkowski RJ, et al. What are the total costs of surgical treatment for uterine fibroids? J Womens Health 2008;17:1119-32
   PubMed Web of Science ®Google Scholar
• Spies JB, Myers ER, Worthington-Kirsch R, et al. The FIBROID registry: symptom and quality-of-life status 1 year after therapy. Obstet Gynecol 2005;106:1309-18
   PubMed Web of Science ®Google Scholar
• Williams VSL, Jones G, Mauskopf J, et al. Uterine fibroids: a review of health-related quality of life assessment. J Womens Health 2006;15:818-29
   PubMed Web of Science ®Google Scholar
• Hehenkamp WJK, Volkers NA, Birnie E, et al. Symptomatic uterine fibroids: treatment with uterine artery embolization or hysterectomy – results from the randomized clinical embolization versus hysterectomy (EMMY) trial. Radiology 2008;246:823-32
   PubMed Web of Science ®Google Scholar
• Spies JB, Coyne K, Guaou NG, et al. The UFS-QOL a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol 2002;99:290-300
   PubMed Web of Science ®Google Scholar
• Popovic M, Berzaczy D, Puchner S, et al. Long-term quality of life assessment among patients undergoing uterine fibroid embolization. Am J Roentgenol 2009;193:267-71
   PubMed Web of Science ®Google Scholar
• Best C, Wolfman W, Singh SS, et al. Abnormal uterine bleeding in pre-menopausal women. JOGC 2013;35:S1-S32
   Google Scholar
• Pundir J, Krishnan N, Siozos A, et al. Peri-operative morbidity associated with abdominal myomectomy for very large fibroid uterus. Eur J Obstet Gynecol Reprod Biol 2013;167:219-94
   PubMed Web of Science ®Google Scholar
• Spies JB, Bradley LD, Guido R, et al. Outcomes from leiomyoma therapies. Obstet Gynecol 2010;116:641-52
   PubMed Web of Science ®Google Scholar
• Tropeano G, Amoroso S, Scambia G. Non-surgical management of uterine fibroids. Hum Reprod Update 2008;14:259-74
   PubMed Web of Science ®Google Scholar
• Product monograph Fibristal™, ulipristal acetate tablet 5mg, Actavis Specialty Pharmaceuticals Co. 2013
   Google Scholar
• Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012;366:409-20
   PubMed Web of Science ®Google Scholar
• Sculpher M. A cost-utility analysis of abdominal hysterectomy versus transcervical endometrial resection for the surgical treatment of menorrhagia. Int J Technol Assess 1998;14:302-19
   PubMed Web of Science ®Google Scholar
• Bansback N, Tsuchiya A, Brazier J, Anis A. Canadian valuation of EQ-5D health states; preliminary value set and considerations for future validation studies. PLoS One 2012;7(2):e31115
   PubMed Web of Science ®Google Scholar
• Van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012;15:708-15
   PubMed Web of Science ®Google Scholar
• Fallowfield L, Atkins L, Catt S, et al. Patients’ preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 2005;17(2):205-20
   PubMed Web of Science ®Google Scholar
• diBonaventura Md, Wagner J-S, Girman CJ, et al. Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication. Patient Prefer Adherence 2010;4:397-406
   PubMed Web of Science ®Google Scholar
• Borner M, Scheithauer W, Twelves C, et al. Answering patients’ needs: oral alternatives to intravenous therapy. Oncologist 2001;6(Suppp 4):12-16
   PubMedGoogle Scholar
• Jones A. Oral therapies are key for boosting treatment compliance in MS. Neurology Rev 2011;19(7):1-31
   Google Scholar
• Tarride JE, Oremus M, Pullenayegum E, et al. How does the Canadian general public rate Moderate Alzheimer’s disease? J Aging Res 2011;2011:682470
   PubMedGoogle Scholar
• Galante J, Augustovski F, Colantonio L, et al. Estimation and comparison of EQ-5D health states’ utility weights for pneumococcal and human papillomavirus diseases in Argentina, Chile and the United Kingdom. Value Health 2011;14:S60-4
   Web of Science ®Google Scholar
• Xie F, Oremus M, Gaebel K. Measuring health-related quality-of-life for Alzheimer’s disease using the general public. Qual Life Res 2011;21(4):593-601
   PubMed Web of Science ®Google Scholar
• Kang HJ, Kang E, Jo MW, et al. The utility score of epilepsy with partial seizure measured by TTO, VAS, and EQ-5D in the general Korean population. Epilepsy Res 2014;108(5):963-71
   PubMed Web of Science ®Google Scholar
• Taylor WJ, Lord S, McPherson KM, McNaughton HK. EuroQol EQ-5D may not adequately describe the health of people with disabilities. Disabil Rehabil 2001;23(7):281-5
   PubMed Web of Science ®Google Scholar
• Wildi SM, Cox MH, Clark LL, et al. Assessment of health state utilities and quality of life in patients with malignant esophageal Dysphagia. Am J Gastroenterol 2004;99(6):1044-9
   PubMed Web of Science ®Google Scholar
• Chancellor J, Aballéa S, Lawrence A, et al. Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens. Pharmacoeconomics 2008;26(3):217-34
   PubMed Web of Science ®Google Scholar
• Guidelines for the economic evaluation of health technologies: Canada 3rd Edition. Ottawa: Canadian Agency for Drugs and Technologies in Health; CA: 2006
   Google Scholar
• Common Drug Review of Ulipristal Acetate for Uterine Fibroids. Available from www.cadth.ca/en/products/cdr?q=SR0326+ [Accessed June 2014]
   Google Scholar